Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT05464082
Recruiting
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Breast Cancer Recurrent
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
NCT05163808
Recruiting
This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).
Gender:
Male
Ages:
Between 9 years and 18 years
Trial Updated:
02/21/2024
Locations: University of Utah and Primary Childrens Hospital, Salt Lake City, Utah
Conditions: Fragile X Syndrome
Register for Updates
Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool
NCT05049330
Recruiting
Cervical spine injuries (CSI) are serious, but rare events in children. Spinal precautions (rigid cervical collar and immobilization on a longboard) in the prehospital setting may be beneficial for children with CSI, but are poorly studied. In contrast, spinal precautions for pediatric trauma patients without CSI are common and may be associated with harm. Spinal precautions result in well-documented adverse physical and physiological sequelae. Of substantial concern is that the mere presence of... Read More
Gender:
All
Ages:
18 years and below
Trial Updated:
02/21/2024
Locations: Primary Children's Medical Center, Salt Lake City, Utah
Conditions: Cervical Spine Injury
Register for Updates
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
NCT05163314
Recruiting
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.
Gender:
All
Ages:
Between 2 years and 56 years
Trial Updated:
02/20/2024
Locations: University of Utah - Primary Children's Hospital - PPDS, Salt Lake City, Utah
Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Register for Updates
Evolutionary Therapy for Rhabdomyosarcoma
NCT04388839
Recruiting
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Gender:
All
Ages:
All
Trial Updated:
02/20/2024
Locations: Primary Children's Medical Center/Utah, Salt Lake City, Utah
Conditions: Rhabdomyosarcoma
Register for Updates
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624
Recruiting
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: START Mountain Region, West Valley City, Utah
Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Register for Updates
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Previously Untreated Acute Myeloid Leukemia
Register for Updates
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities
NCT05361941
Recruiting
This is a pivotal, prospective, multi-center, randomized, concurrent control, patient and assessor-blinded study with two arms: a treatment arm (where subjects will be treated with the EP Granules with Tobramycin investigational device in the 1st stage of a 2-stage surgical treatment for periprosthetic joint infection (PJIs), and a control arm (where subjects are treated with the standard-of-care 2-stage surgical treatment for infected PJIs).
Gender:
All
Ages:
22 years and above
Trial Updated:
02/19/2024
Locations: Jordan Valley Medical Center, West Jordan, Utah
Conditions: Periprosthetic Joint Infections
Register for Updates
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
NCT03805789
Recruiting
This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/19/2024
Locations: University of Utah Primary Children's Hospital, Salt Lake City, Utah
Conditions: Acute-graft-versus-host Disease
Register for Updates
Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
NCT06241742
Recruiting
The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal. The main question it aims to answer are: Does HT-6184 decrease inflammation in patients after third molar removal? Does HT-6184 decrease pain in patients after third molar removal? Participants will be asked to do the following during the clinical trial: Take a single oral dose of HT-6184 or placebo Allow a oral surgeon remove their third molar teeth Bloo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: CenExel JBR, Murray, Utah
Conditions: Pain
Register for Updates